Clinical trial
A Post-Marketing Surveillance Study on the Safety, Tolerability and Efficacy of Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
NCT01826370 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Post-Marketing Surveillance Study on the Safety, Tolerability and Efficacy of Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Observational
- Overall status
- Terminated
- Start date
- May 31, 2012
- Completion date
- October 31, 2013
- Enrollment
- 678 (actual)
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.